# Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

> **NCT04826107** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 196 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** DP303c treatment
- **DRUG:** DP303c treatment（second-line of HER2-positive）
- **DRUG:** DP303c treatment （third-line of HER2-positive）
- **DRUG:** DP303c treatment（≥second-line of HER2 low expressing）
- **DRUG:** DP303c + PD-1/PD-L1 treatment

## Key facts

- **NCT ID:** NCT04826107
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08
- **Primary completion:** 2024-08
- **Final completion:** 2024-12
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826107, "Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04826107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*